目的观察长春瑞滨联合顺铂治疗晚期非小细胞肺癌的疗效及不良反应。方法对入选的48例晚期非小细胞肺癌患者行长春瑞滨联合顺铂化疗。结果完全缓解(CR)2例,部分缓解(PR)21例,稳定(NC)19例,进展(PD)6例,总有效率为47.91%。其中初治患者有效率为52.94%,复治患者有效率为35.71%。主要不良反应为骨髓抑制,注射部位静脉反应及恶心、呕吐、便秘等。结论长春瑞滨联合顺铂治疗晚期非小细胞肺癌疗效好,不良反应轻。 Objective To observe the efficacy and adverse reactions of vinorelbine plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods 48 patients with advanced non-small cell lung cancer were treated with vinorelbine and cisplatin. Results There were 2 cases of complete remission (CR), 21 cases of partial remission (PR), 19 cases of stable (NC) and 6 cases of progressive (PD). The total effective rate was 47.91%. Among them, the effective rate of newly diagnosed patients was 52.94%, and the effective rate of retreatment patients was 35.71%. The main adverse reactions were myelosuppression, venous injection and nausea, vomiting and constipation. Conclusion Vinorelbine combined with cisplatin in the treatment of advanced non-small cell lung cancer has good efficacy and mild adverse reactions.